osimertinib
astrazeneca
['adaura']
 tbh, i thought the results from this study &amp; others reported in this space have been underwhelming, showing major path response rate &lt;20%. we'll need to see what ph3 data show, but this is not in the ballpark of the screamingly positive kind of result we've seen with adaura.
Med Onc,@CityofHope; VP Netwk Strategy AccessHope, Founder,@CancerGRACE; Web Ed,@JAMAOnc; Author/Ed, @UptoDate

Telemed/digital med fan. 
Disclosures @ website